mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-24. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
=== United States === In 1993, the product was approved for use in the US by the FDA, and its use began in 1994. The product is now sold in all 50 states. The FDA stated that food products made from rBST-treated cows are safe for human consumption, and no statistically significant difference exists between milk derived from rBST-treated and untreated cows. The FDA found BST to be biologically inactive when consumed by humans and found no biological distinction between rBST and BST. In 1990, an independent panel convened by the National Institute of Health supported the FDA opinion that milk and meat from cows supplemented with rBST is safe for human consumption.
Daisho (Dso) is an antimicrobial peptide gene family of the fruit fly Drosophila melanogaster. Two Daisho genes (Dso1, Dso2) are encoded in tandem in the fruit fly genome, one shorter than the other. This pair of genes with different length was named "Daisho" in reference to Daisho Japanese swords, which come in pairs with one shorter than the other. The Daisho genes are regulated by Drosophila Toll-like receptor signalling. Daisho peptides protect flies against filamentous fungi, particularly Fusarium and also Aspergillus. Daisho peptides are part of the Drosophila antifungal effector peptide response, which includes the gene families Bomanin, Drosomycin, Metchnikowin, and Baramicin.
==== Structured breast prosthesis ==== The fourth category of prosthetic-breast technology is the structured breast-prosthesis, which was approved for breast surgery by the Food and Drug Administration in the U.S. and by Health Canada in Canada in 2014. As a medical device, the structured prosthetic-breast incorporates the technologies of saline-solution and of silicone-gel to achieve anatomical function and aesthetic symmetry. Technologically, the internal structure of the breast prosthesis is composed of three, nested shells (made of silicone rubber) that support the upper half of the breast hemisphere; the two spaces between the three nested shells is filled with saline solution. To implant a structured breast prosthesis, the plastic surgeon emplaces the folded, empty prosthetic breast into the implant-socket, then fills the prosthetic breast with saline solution, and afterwards sutures shut the insertion incision.
== Distribution == In humans, sarcosine is found at relatively low concentrations in the extracellular compartment, mitochondria, and peroxisomes. Tissues with measurable sarcosine concentrations include skeletal muscle and the prostate gland. Its cellular levels are tightly regulated by the balance between GNMT-mediated synthesis and SARDH/PIPOX-mediated catabolism.
Sources: en.wikipedia.org
Chondrocytes (, from Greek χόνδρος (chondros) 'cartilage' and κύτος (kytos) 'cell') are the only cells found in healthy cartilage. They produce and maintain the cartilaginous matrix, which consists mainly of collagen and proteoglycans. Although the word chondroblast is commonly used to describe an immature chondrocyte, the term is imprecise, since the progenitor of chondrocytes (which are mesenchymal stem cells) can differentiate into various cell types, including osteoblasts.
Bhattacharjee, S., Mukherjee, S., and Roy, S.* (2021) J Phys Chem B, 125, 5832-5837.https://doi.org/10.1021/acs.jpcb.1c03794 A peptide-based synthetic transcription factor selectively activates transcription in a mammalian cell. Roy, K., Mazumder, A., Ghosh, P., Naiya, G., Ghosh, B., & Roy, S.* (2018) Chem Commun. 54, 1611-1614.https://doi.org/10.1039/C7CC09279B A Peptide-based Synthetic Transcription Factor Selectively Down-regulates the Proto-oncogene CFOS in Tumour Cells and Inhibits Proliferation. Chakraborty, M. and Roy, S.* (2016) Chem Commun, 53, 376-379.https://doi.org/10.1039/C6CC08086C Specific Sequence of a Beta-turn in Human La Protein May Contribute to Species Specificity of Hepatitis C Virus. Kumar, A., Manna, AK., Ray, U., Mullick, R., Basu, G., Das, S., & Roy, S.* (2014) J Virol, 88, 4319-27. https://doi.org/10.1128/jvi.00049-14 A Synthetic Peptide Mimic of l-Cro shows Sequence-Specific Binding in vitro and in vivo. Mazumder, A., Maiti, A., Roy, K., & Roy, S.* (2012) ACS Chem Biol, 7, 1084-94. https://doi.org/10.1021/cb200523n Peptide-protein interactions suggest that acetylation of lysines 381 and 382 of p53 is important for positive coactivator 4/p53 interaction. Debnath, S., Chatterjee, S., Arif, M., Kundu, TK., & Roy, S.* (2011) J Biol Chem, 286, 25076-87.https://doi.org/10.1074/jbc.M110.205328 Differential recognition of phosphorylated transactivation domains of p53 by different p300 domains. Polley, S., Guha, S., Roy, NS., Kar, S., Sakaguch,i K., Chuman, Y., Swaminathan, V., Kundu, T., & Roy, S.* (2008) J Mol Biol, 376, 8-12.
South of Centro stands the Crocetta district, considered one of the most exclusive districts of the city, because of highly rated residential buildings. At the heart of the district is the partially pedestrianised area crossed by Corso Trieste, Corso Trento and Corso Duca D'Aosta, plenty of some notable residential buildings in eclectic, neo-Gothic and Art Nouveau style. The area was built between 1903 and 1937 replacing the old parade ground, which was moved in the southern part of the city. North of this area stands the GAM (Galleria d'Arte Moderna), one of the two Museum of Modern Arts of the Turin Metro area (the second and largest one is hosted in Castello di Rivoli, a former Savoy royal castle in the suburbs). The museum stands in front a huge monument situated in the centre of the roundabout between Corso Vittorio Emanuele II and Corso Galileo Ferraris: the Monument to Vittorio Emanuele II, a king of Savoy statue situated on a 39-metres high column. Next to the museum, another significant residential building previously hosted the head office of Juventus, one of the two main Turin football clubs. West of this area, the main building of Polytechnic University of Turin stands along Corso Duca Degli Abruzzi. The 1958 building, a 122,000 m2 (1,313,197 sq ft) complex, hosts approximately 30,000 students and is considered one of the major institutes of technology of the country—mainly due to the vocation of the city for the industrialisation, pushed by the automotive sector.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.